Physician profile
Robert M Gelfand
NPI 1407855612
$39,179.12
in general payments reported to CMS, 2019-2025
91 companies · $4,213 in 2025
The $4,213 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $2,575 · 2021: $4,623 · 2022: $3,314 · 2023: $4,074 · 2024: $3,189 · 2025: $4,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $299 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,010.45 |
| Education | $298.94 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13,777.24 | 2019-2025 | Entyvio, Hyqvia |
| Amgen INC. | $3,873.14 | 2019-2025 | Evenity, Prolia, Uplizna |
| Novartis Pharmaceuticals Corporation | $2,394.75 | 2019-2025 | |
| Janssen Biotech, INC. | $1,965.77 | 2019-2025 | Darzalex, Rybrevant, Talvey |
| Astrazeneca Pharmaceuticals Lp | $1,627.80 | 2019-2025 | Saphnelo, Calquence, Enhertu |
| Genzyme Corporation | $1,209.62 | 2019-2025 | |
| Lilly USA, LLC | $928.21 | 2019-2025 | Omvoh, Verzenio, Jaypirca |
| Celgene Corporation | $915.32 | 2019-2025 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $738.68 | 2020-2024 | Enhertu, Injectafer |
| Genentech USA, INC. | $716.34 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Glaxosmithkline, LLC. | $582.72 | 2019-2025 | Ojjaara, Nucala, Benlysta |
| Lundbeck LLC | $563.36 | 2020-2025 | Vyepti |
| E.R. Squibb & Sons, L.L.C. | $536.32 | 2019-2024 | Opdivo, Opdualag, Eliquis |
| Seagen INC. | $512.31 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Incyte Corporation | $469.78 | 2019-2025 | Jakafi |
Show all 91 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gelfand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.